Research summaries for everyoneNot medical advice
Tesamorelin research reference vial, Elevated Pharma

Research reference · Hormones

Tesamorelin

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone and the active ingredient in FDA-approved Egrifta, used for excess abdominal fat in people with HIV.

Published by Elevated Pharma ·

HormonesFDA-labeled drug reference

Identity

What is Tesamorelin?

A synthetic GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group (development code TH9507).

Research context

What has Tesamorelin been studied for?

Randomized trials in people with HIV cover visceral fat, fatty liver and neurocognition; smaller studies examine people without HIV.

Evidence boundary

What does the research not show?

Approval of a prescription product does not transfer to an unlabeled research material.

U.S. status · November 7, 2026

Is Tesamorelin FDA-approved?

FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing information is the controlling source.

Key studies

The main Tesamorelin research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 95 PubMed records for Tesamorelin · Counts and selections checked November 7, 2026.

Reference identifiers

Tesamorelin identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
Tesamorelin
Also indexed as
TH9507
Molecular formula
C221H366N72O67S
Molecular mass
5136 g/mol
PubChem CID
16137828

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.